Research Pulse — 2026-10-09 | Brown Biotech

# Research Pulse — 2026-10-09
_Generated 2026-10-09 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 10월 9일 (금요일) · Translating(임상 전환) Day**

10/09(임상 전환) → 10/08(성숙) → 10/07(산업화) → 10/06(산업화) → 10/05(확장) → 10/04(가속) → 10/03(수렴) → 10/02(정착). Maturing(10/08)된 기술들이 **실제 임상 데이터 축적과 규제 승인으로의 이행(Translating)의 단계로 진입하는 날** — Şahin et al.로 CRISPR therapeutics global trajectory 분석 — ClinicalTrials.gov/EU Clinical Trials Register 등록 700건 이상 + manufacturing/regulatory/economic challenges 지속 + COST GenE-HumDi initiative(Molecular Therapy. Nucleic Acids 2026), Oo et al.로 FDA Gene Therapy Approvals 1998-2025 종합 — 44개 CGT 승인(2025년 5월 기준) + AI/ML dose selection·safety evaluation·durability prediction convergence + platform-aligned risk-based approach(J Clinical Pharmacology 2026), Seyhan et al.로 AI drug discovery Phase I/II候补 동시 존재 + AI-discovered candidates 임상 진행 현황 + algorithmic transparency·data quality 규제 수용성 조건(Critical Reviews Oncology Hematology 2026), Feldman et al.로 AlphaFold3 adversarial sequence mutations 평가 — 40% residues 점변이나 구조 불변 + confidence metrics 35%만 정확 + ESMFold 상대적 우위 확인(Computational Structural Biotechnology Journal 2026), Ji et al.로 CAPTAIN multimodal foundation model — 4M+ cells에서 transcriptomes + 382 proteins 동시 측정 + protein imputation·expansion·cell type annotation·batch harmonization(Nature Communications 2026), Şahin et al.로 CRISPR off-target monitoring toolkit 종합 — preclinical-to-clinical toolkits + on/off-target measurement + microphysiological systems + in vivo imaging(Nature Reviews Genetics 2026), Kunanayagam et al.로 FDA CGT 44개 중 14개 pediatric 적용 + vector shedding·biodistribution·cellular kinetics 소아 특이 고려사항(Pediatric Research 2026), Zhang et al.로 SCLC CosMx spatial atlas — 75명 105개 검체 600K+ cells + 3개 LNM-enriched malignant subclusters + PIHs-1 survival predictor + vascular-immune crosstalk(Cell Reports Medicine 2026)이 동시에 진행된다.

Translating은 Maturing의 다음 단계다. 오늘 6개 전선은 성숙된 기술들이 **실제 임상 데이터 축적, 규제 승인 현실, AI候补 임상 Phase I/II 진입, 환자 규모 적용(Translating)으로 이행하며, 기술의 임상 전환 가능성을 실제 데이터로 증명하는 날**이다.

*출처: [Şahin CRISPR Global Trajectory Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Feldman AlphaFold Adversarial Mutations Computational Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Ji CAPTAIN Multimodal Foundation Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Şahin CRISPR Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Kunanayagam FDA CGT Pediatric Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/), [Zhang SCLC CosMx Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)*

*#TranslatingDay #Şahin #CRISPR #MolecularTherapyNucleicAcids #GlobalTrajectory #ClinicalTrials #700Trials #Manufacturing #Regulatory #EconomicChallenges #GenEHumDi #Oo #FDA #JClinicalPharmacology #44CGTApprovals #PlatformAligned #AIAnalytics #DoseSelection #SafetyEvaluation #DurabilityPrediction #Seyhan #CriticalReviews #OncologyHematology #PhaseI #PhaseII #AlgorithmicTransparency #DataQuality #RegulatoryAcceptance #Feldman #AlphaFold3 #AdversarialMutations #ComputationalStructuralBiotechnology #StructuralInvariance #ConfidenceMetrics #ESMFold #Ji #CAPTAIN #NatureCommunications #Multimodal #Transcriptome #Protein #382Proteins #4MillionCells #Şahin #MonitoringToolkit #Preclinical #Clinical #Microphysiological #InVivoImaging #NatureReviewsGenetics #Kunanayagam #PediatricResearch #VectorShedding #Biodistribution #CellularKinetics #Zhang #CosMx #SCLC #600KCells #75Patients #PIHs1 #VascularImmune #Crosstalk #Translating #ClinicalTranslation #RealWorldData #RegulatoryApproval #BiomedicalAI #DailyReport*

---

### Post 2: CRISPR & Gene Editing — Global Clinical Trial Landscape × Off-Target Monitoring Toolkit: Translating

🪄 **[CRISPR/Gene Editing] Şahin et al.로 CRISPR therapeutics global trajectory — ClinicalTrials.gov/EU Clinical Trials Register 등록 700건 이상 + 30개 이상 국가 + 기술/규제/경제적 도전 과제 지속(Molecular Therapy. Nucleic Acids 2026) + Şahin et al.로 CRISPR off-target monitoring toolkit 종합 — preclinical-to-clinical toolkits + DNA on/off-target measurement + microphysiological systems + non-invasive in vivo imaging(Nature Reviews Genetics 2026) + Kunanayagam et al.로 FDA CGT 44개 승인 중 14개 pediatric 적용 + vector shedding·biodistribution·cellular kinetics 소아 고려사항(Pediatric Research 2026): CRISPR Translating(임상 전환) 동시 확인**

CRISPR gene therapy의 **global 임상 trials 현황 + off-target monitoring 체계 + pediatric 적용 현실(Translating)**이 출처에서 동시에 확인된다[1][6][7].

**CRISPR Therapeutics Global Trajectory: 700건 이상 임상 Trials[1]**
Ceren Şahin et al.(Molecular Therapy. Nucleic Acids 2026)의 연구는 CRISPR therapeutics의 global trajectory를 종합한다[1]. **ClinicalTrials.gov + EU Clinical Trials Register 등록 700건 이상** 확인 — 전 세계적 임상 개발 활발. **30개 이상 국가에서 trials 진행**. **기술적 도전 과제**: delivery systems 한계, off-target effects 관리, 장기 안전성 확립. **규제적 도전 과제**: 각국 별도 승인 체계, 통일된 표준 부재. **경제적 도전 과제**: 고가 치료제 가격, 환자 접근성, 보험 적용 문제. **COST GenE-HumDi initiative**: 유럽 협력 과학 기술_framework로 genome editing 기술의 임상 적용 가속화 목표. 핵심: CRISPR therapeutics global trajectory 700건 이상 trials + 기술/규제/경제적 도전 과제 — 임상 전환 현실.

**CRISPR Off-Target Monitoring Toolkit: Preclinical-to-Clinical Bridge[6]**
Ceren Şahin et al.(Nature Reviews Genetics 2026)의 review는 CRISPR 기반 게놱 편집 치료제의 안전성 평가를 위한 toolkit을 종합한다[6]. **Preclinical-to-clinical toolkits 필요성**: 편집 결과 측정 기술이 임상 전환에 필수. **On-target measurement**: 편집 위치에서의 실제 효과 측정. **Off-target measurement**: 의도치 않은 편집 위치 식별 및 빈도 측정. **Microphysiological systems**: organoids, organs-on-chips로 표현형 평가. **Non-invasive in vivo imaging**: 편집 분포 추적. **Single nucleotide에서 whole organism까지**: 측정 스케일 통합. 핵심: CRISPR off-target monitoring toolkit — 임상 안전성 평가 체계 확립.

**FDA CGT 14개 Pediatric Approvals: Vector Shedding·Cellular Kinetics[7]**
S. Kunanayagam et al.(Pediatric Research 2026)을 재확인한다[7]. **44개 CGT 승인 중 14개(약 32%)가 pediatric 적용**. **In vivo gene therapy**: vector shedding과 biodistribution 고려 필요. **Ex vivo gene therapy**: cellular kinetics — expansion과 persistence가 CAR-T/TIL에서 핵심. **First-in-human dosing**: related therapies 데이터로 guide. 핵심: FDA CGT pediatric 14개 적용 + 소아 특이적 고려사항 — 임상 전환 현실.

**10월 8일 Maturing(Haldrup LVNPs + Cetin Casgevy + Fakiyesi cardiovascular) vs 오늘의 차별점**: 10/08이 **Haldrup Nucleic Acids Research**으로 LVNPs RNP 전달 체계 확립을, **Cetin Expert Reviews**으로 Casgevy FDA 승인 이후 임상 trials 현황을, **Fakiyesi Cureus**으로 심혈관 질환 적용 전달 특이성 과제를 제시했다면, 오늘은 **Şahin Molecular Therapy Nucleic Acids**으로 **700건 이상 global clinical trials 등록 현황 + 기술/규제/경제적 도전 과제 체계**를(임상 전환 현실), **Şahin Nature Reviews Genetics**으로 **preclinical-to-clinical off-target monitoring toolkit 체계**를(안전성 평가 체계 임상 전환), **Kunanayagam 재확인**으로 **14개 pediatric 적용 + vector shedding/cellular kinetics 소아 고려사항**을(소아 임상 전환) 동시에 제시한다. Maturing(10/08) → global trials 현황 + monitoring toolkit + pediatric 적용 Translating(10/09).

실무 함의: 유전자 치료 개발팀에서 Şahin et al.의 global clinical trials 현황을 참조하여 international trial strategy를 수립해야 한다.

*출처: [Şahin CRISPR Global Trajectory Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/), [Şahin CRISPR Monitoring Toolkit Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Kunanayagam FDA CGT Pediatric Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)*

*#CRISPR #GeneEditing #Şahin #MolecularTherapyNucleicAcids #GlobalTrajectory #700Trials #ClinicalTrials #COST #GenEHumDi #NatureReviewsGenetics #OffTarget #Monitoring #Preclinical #Clinical #Toolkit #Microphysiological #Organoids #OrgansOnChips #InVivoImaging #OnTarget #OffTarget #Kunanayagam #PediatricResearch #FDA #CGT #44Approvals #14Pediatric #VectorShedding #Biodistribution #CellularKinetics #CAR-T #TIL #TranslatingDay #ClinicalTranslation #GlobalTrials #SafetyAssessment #BiomedicalAI #DailyReport*

---

### Post 3: AI 신약 — Phase I/II 동시 존재 × Clinical Translation 현실: Translating

💊 **[AI 신약] Seyhan et al.로 AI drug discovery Phase I/II候补 동시 존재 — AI-originated Phase IIa efficacy + Phase I safety stop 동시 + 0건 완전 마케팅 승인 + algorithmic transparency·data quality 규제 수용성 조건(Critical Reviews Oncology Hematology 2026) + Mao et al.로 AI候补 Phase IIa encouraging efficacy + Phase I safety signals + AI 독성 earlier detection 가능하나完全 elimination 불가 현실(Frontiers in Pharmacology 2026) + Ali et al.로 AI-Pharma collaborative models 필수 + algorithmic transparency + data quality + regulatory acceptance 조건(Expert Opinion Drug Discovery 2026): AI Drug Discovery Translating(임상 전환) 동시 확인**

AI-Driven Drug Discovery의 **Phase I/II候补 동시 존재 + 임상 전환 현실(Translating)**이 출처에서 동시에 확인된다[2][3][4].

**AI Drug Discovery Phase I/II 동시 존재: 0건 완전 마케팅 승인[2]**
A. Seyhan et al.(Critical Reviews in Oncology/Hematology 2026)의 review는 AI drug discovery의 임상 번역 현황을 종합한다[2]. **AI-discovered/designed候补가 Phase I과 Phase IIa에 동시 존재**: encouraging efficacy를 보인候补와 safety signals로 정지된候补가 동시에 존재. **완전 AI 발견/설계 약물의 마케팅 승인 0건**: 현실적 제약 확인. **Algorithmic transparency**: 규제 수용성 조건. **Data quality**: 모델 신뢰성 기반. **Cross-disciplinary training 필요**: ML + pharmaceutics 인력 부족. 핵심: AI drug discovery Phase I/II 동시 존재 + 0건 완전 마케팅 승인 — 임상 전환 현실.

**AI候补 Phase IIa Efficacy + Phase I Safety Stop 동시 존재[3]**
Zihan Mao et al.(Frontiers in Pharmacology 2026)의 review를 재확인한다[3]. **한候补 Phase IIa에서 encouraging efficacy**: AI 발견/설계候补의 첫 성과. **다른候补 Phase I에서 safety signals로 정지**: 제한적 성공. **AI 독성 earlier detection 가능하나完全 elimination 불가**: biological complexity, patchy data, ML+pharmaceutics 인력 부족. **Algorithmic transparency + data quality**: 규제 수용성 조건. 핵심: Phase IIa efficacy + Phase I safety stop 동시 존재 — 임상 전환 현실.

**AI-Pharma Collaborative Models: 필수 조건[4]**
M. Ali et al.(Expert Opinion on Drug Discovery 2026)의 review를 재확인한다[4]. **AI developers + pharmaceutical industries collaborative models가 translational outcomes加速에 필수**. **Algorithmic transparency**: 규제 승인의 전제 조건. **Data quality**: 모델 신뢰성 기반. **Regulatory acceptance**: 승인을 위한 관료적 요구사항. **Challenges**: interoperability, cross-disciplinary training 부족. 핵심: AI-Pharma collaborative models 필수 조건 + 규제 수용성 — 임상 협력 체계.

**10월 8일 Maturing(Chen LLM DMTA + Wei PerturbNet + Ahlmann-Eltze linear baselines) vs 오늘의 차별점**: 10/08이 **Chen Drug Discovery Today**으로 LLM molecular design + autonomous DMTA를, **Wei Nature Methods**으로 PerturbNet DE 최고 + cross-cell type generalization 실패를, **Ahlmann-Eltze Nature Methods**으로 5개 foundation models linear baselines 능가하지 못함을 제시했다면, 오늘은 **Seyhan Critical Reviews**으로 **Phase I/II候补 동시 존재 + 0건 완전 마케팅 승인**이라는 임상 전환 현실(Translating)을, **Mao Frontiers Pharmacology 재확인**으로 **Phase IIa efficacy + Phase I safety stop 동시**라는 구체적候补 상황(Translating)을, **Ali Expert Opinion 재확인**으로 **algorithmic transparency + data quality 규제 수용성 조건**이라는 협력 체계(Translating)를 동시에 제시한다. Maturing(10/08) → Phase I/II 동시 존재 + 임상 전환 현실 + 협력 조건 Translating(10/09).

실무 함의: AI drug discovery 협업팀에서 Seyhan et al.의 Phase I/II候补 현황을 참조하여候补 development strategy를 수립해야 한다.

*출처: [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Mao AI Drug Discovery Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Ali AI Drug Discovery Expert Opinion Drug Discovery 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/)*

*#AI #DrugDiscovery #Seyhan #CriticalReviews #OncologyHematology #PhaseI #PhaseII #AlgorithmicTransparency #DataQuality #RegulatoryAcceptance #Mao #FrontiersinPharmacology #PhaseIIa #PhaseI #SafetyStop #Efficacy #Ali #ExpertOpinion #CollaborativeModels #AIPharma #TranslatingDay #ClinicalTranslation #CandidatePipeline #RegulatoryConditions #BiomedicalAI #DailyReport*

---

### Post 4: 단백질 AI — AlphaFold3 Adversarial Vulnerability × Confidence Audit: Translating

🔬 **[단백질 AI] Feldman et al.로 AlphaFold3 adversarial sequence mutations 평가 — 40% residues 점변이나 구조 불변 + confidence metrics 35%만 정확 + ESMFold 상대적 우위 확인(Computational Structural Biotechnology Journal 2026) + Yin et al.로 AlphaFold3 drug discovery 적용 종합 — ESMFold 속도/확장성 + current challenges(Frontiers Molecular Biosciences 2026) + Abramson et al.로 AlphaFold3 protein-ligand interactions大幅改善(Nature 2024): 단백질 AI Translating(임상 전환) 동시 확인**

단백질 AI의 **AlphaFold3 adversarial vulnerability 현실 + confidence audit(Translating)**이 출처에서 동시에 확인된다[5][8][9].

**AlphaFold3 Adversarial Mutations: Structural Invariance + Confidence Failure[5]**
Jonathan Feldman et al.(Computational Structural Biotechnology Journal 2026)의 연구는 AlphaFold3의 adversarial evaluation을 수행한다[5]. **40% residues 점변이나 구조 불변**: 의도적 destabilizing substitutions에도 불구. **10% deletion에도 불변**: protein folding invariance. **Fold-switching proteins에서도 불변**: alternative conformations adoption 안 됨. **Confidence metrics 35%만 정확**: 가장 정확한 구조 선택 35%만 가능. **Training-set template와 상관관계**: confidence와 structural quality 불일치. **ESMFold 상대적 우위**: 더 큰 mutation sensitivity 있으나 불완전. **Implications**: mutation-effect interpretation, confidence-guided model selection, sequence optimization workflow에 직접적 영향. 핵심: AlphaFold3 adversarial vulnerability + confidence metrics failure — 임상 적용 신뢰성 과제.

**AlphaFold3 Applications: ESMFold 속도/확장성 + Drug Discovery 적용[8]**
Tianxiang Yin et al.(Frontiers in Molecular Biosciences 2026)을 재확인한다[8]. **ESMFold**: single-sequence approach로 속도와 확장성 크게 향상. **Drug discovery 적용**: 단백질-리간드 상호작용 예측. **Enzyme engineering**: 촉매 효율 최적화. **Disease research**: 질환 관련 단백질 구조 분석. **Current challenges**: protein dynamics modeling, incomplete annotation, conformational flexibility. 핵심: AlphaFold3 applications + ESMFold 속도/확장성 — 단백질 AI 적용 현실.

**AlphaFold3 Protein-Ligand Interactions大幅改善[9]**
Josh Abramson et al.(Nature 2024)을 재확인한다[9]. **Protein-ligand interactions**: state-of-the-art docking tools 대비大幅改善. **Protein-nucleic acid interactions**: 크게 향상. **Antibody-antigen prediction**: AlphaFold-Multimer v2.37 대비 현저히 향상. **단일 unified framework**: proteins, nucleic acids, small molecules, ions, modified residues 모두 예측. 핵심: AlphaFold3 protein-ligand interactions大幅改善 — 단백질 AI 성능 현실.

**10월 8일 Maturing(Yin AlphaFold3 applications + Abramson AF3 improvements + Chakraborty AF3 evolution) vs 오늘의 차별점**: 10/08이 **Yin Frontiers Molecular Biosciences**으로 AlphaFold3 applications 종합을, **Abramson Nature**으로 protein-ligand interactions改善를, **Chakraborty Nature Biotechnology**으로 AF3 evolution을 제시했다면, 오늘은 **Feldman Computational Structural Biotechnology**으로 **AlphaFold3 40% residues 점변이나 구조 불변 + confidence metrics 35%만 정확**이라는 adversarial vulnerability(Translating — 신뢰성 임상 적용 과제)를, 같은 **Yin/Abramson 재확인**으로 **ESMFold 우위 + AF3 성능改善의 구체적 수치**를(성능 vs 신뢰성 duality — Translating) 동시에 제시한다. Maturing(10/08) → AlphaFold3 adversarial vulnerability + confidence failure + 성능改善 duality Translating(10/09).

실무 함의: SBDD 워크플로우팀에서 Feldman et al.의 adversarial mutation 결과를 AlphaFold confidence interpretation strategy에 반영해야 한다.

*출처: [Feldman AlphaFold3 Adversarial Mutations Computational Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Yin AlphaFold3 Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Abramson AlphaFold3 Nature 2024](https://consensus.app/papers/details/48c459ae935b59ea9a75d3647ba7d47b/)*

*#ProteinAI #AlphaFold #Feldman #ComputationalStructuralBiotechnology #AdversarialMutations #StructuralInvariance #40Percent #ConfidenceMetrics #35Percent #ESMFold #MutationSensitivity #TrainingSet #Template #Yin #Frontiers #MolecularBiosciences #ESMFold #Speed #Scalability #DrugDiscovery #EnzymeEngineering #Abramson #Nature #AlphaFold3 #ProteinLigand #Improved #UnifiedFramework #TranslatingDay #AdversarialVulnerability #ConfidenceFailure #SBDD #BiomedicalAI #DailyReport*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — CAPTAIN Multimodal × SCMBench Benchmarking: Translating

🬬 **[Single-Cell Multi-Omics Foundation Model] Ji et al.로 CAPTAIN multimodal foundation model — 4M+ cells에서 transcriptomes + 382 proteins 동시 측정 + protein imputation·expansion·cell type annotation·batch harmonization(Nature Communications 2026) + Wang et al.로 SCMBench 23 methods — FMs < DMs in multi-omics integration + lightweight adaptation으로 FM 성능 향상(Nature Communications 2026) + Cen et al.로 single-cell + spatial omics methods/applications 종합 — generative AI + foundation models + multi-omics integration algorithms(MedComm 2026): foundation model Translating(임상 전환) 동시 확인**

Single-Cell Foundation Model의 **CAPTAIN multimodal (transcriptome + protein) + benchmarking 현실(Translating)**이 출처에서 동시에 확인된다[10][11][12].

**CAPTAIN: Multimodal Transcriptome + Protein Foundation Model[10]**
Bo-Ya Ji et al.(Nature Communications 2026)의 연구는 CAPTAIN을 제시한다[10]. **4M+ cells에서 동시 측정**: transcriptomes + 382 proteins. **동시 측정**: concurrently measured single-cell RNA + surface proteins. **Cross-modality dependencies modeling**: unified multimodal representations 학습. **Protein imputation**: 전사체에서 단백질 수준 예측. **Protein expansion**: 기존 데이터에서 단백질 보강. **Cell type annotation**: 세포 유형 주석 개선. **Batch harmonization**: 배치 효과 보정. **COVID-19 severity 관련 immune interaction patterns**: 단백질-유전체 통합으로才发现. 핵심: CAPTAIN multimodal (transcriptome + 382 proteins) foundation model — 임상 적용 가능한 통합 분석.

**SCMBench: FMs < DMs in Multi-Omics Integration + Lightweight Adaptation[11]**
Yixuan Wang et al.(Nature Communications 2026)의 SCMBench를 재확인한다[11]. **23개 방법 평가**: integration accuracy, biomarker detection, trajectory inference, batch effect correction. **FMs < DMs**: foundation models가 domain-specific models보다 낮은 성능. **Lightweight adaptation strategy**: FM 성능 향상 가능. 핵심: SCMBench FMs < DMs + lightweight adaptation — benchmarking 현실.

**Single-Cell + Spatial Omics: Generative AI + Foundation Models[12]**
Xiaoping Cen et al.(MedComm 2026)의 review를 재확인한다[12]. **Generative AI + foundation models**: multimodal multiomics data manipulation. **Multi-omics integration algorithms**: single-cell + spatial analyses. **Applications**: biomarker discovery, therapeutic target identification, precision medicine. 핵심: single-cell + spatial omics computational advances — 적용 확대.

**10월 8일 Maturing(Wei PerturbNet + Ahlmann-Eltze + Weng confidence) vs 오늘의 차별점**: 10/08이 **Wei Nature Methods**으로 PerturbNet DE 최고 + cross-cell type generalization 실패를, **Ahlmann-Eltze Nature Methods**으로 5개 foundation models linear baselines 능가하지 못함을, **Weng bioRxiv**으로 frozen scFM confidence audit를 제시했다면, 오늘은 **Ji Nature Communications**으로 **CAPTAIN — 4M+ cells에서 transcriptomes + 382 proteins 동시 측정**이라는 새로운 multimodal 관점(Translating)을, **Wang 재확인**으로 **FMs < DMs + lightweight adaptation** benchmarking 현실을(Translating), **Cen 재확인**으로 **generative AI + foundation models + multi-omics integration** 적용 확대를(Translating) 동시에 제시한다. Maturing(10/08) → CAPTAIN multimodal + benchmarking 현실 + 적용 확대 Translating(10/09).

실무 함의: 단일세포 연구팀에서 Ji et al.의 CAPTAIN 접근법을 multimodal analysis strategy에 적용해야 한다.

*출처: [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)*

*#SingleCell #FoundationModel #Ji #CAPTAIN #NatureCommunications #Multimodal #Transcriptome #Protein #382Proteins #4MillionCells #Imputation #Expansion #CellTypeAnnotation #BatchHarmonization #COVID19 #ImmuneInteraction #Wang #SCMBench #NatureCommunications #FMsLessThanDMs #LightweightAdaptation #23Methods #Cen #MedComm #GenerativeAI #FoundationModels #MultiOmics #Integration #Spatial #TranslatingDay #MultimodalIntegration #ClinicalTranslation #BiomedicalAI #DailyReport*

---

### Post 6: FDA/규제 — 44 CGT Approvals × Platform-Aligned AI/ML Analytics: Translating

📋 **[FDA/규제] Oo et al.로 FDA Gene Therapy Approvals 1998-2025 — 44개 CGT 승인(2025년 5월 기준) + platform-aligned risk-based approach + AI/ML dose selection·safety evaluation·durability prediction convergence(J Clinical Pharmacology 2026) + Shahzad et al.로 FDA CGT 38개 approval assessment — 86.8% orphan + 92.1% expedited + 73.7% single pivotal study + 44.7% surrogate endpoints + 73.4% PMR/PMC(Clinical Pharmacology Therapeutics 2026) + Kunanayagam et al.로 FDA CGT 44개 중 14개 pediatric + vector shedding·biodistribution·cellular kinetics 소아 고려사항(Pediatric Research 2026): FDA/규제 Translating(임상 전환) 동시 확인**

FDA 규제 영역의 **44개 CGT 승인 현실 + AI/ML analytics convergence + pediatric 적용(Translating)**이 출처에서 동시에 확인된다[13][14][7].

**FDA Gene Therapy Approvals 44개: Platform-Aligned AI/ML Analytics[13]**
C. Oo et al.(J Clinical Pharmacology 2026)의 review를 재확인한다[13]. **44개 CGT 승인(2025년 5월 기준)**: Gene therapy의 본격적 임상 적용 확인. **Platform-aligned, risk-based approach**: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **AI/ML-enabled analytics**: dose selection, safety evaluation, durability prediction convergence. **Individualized, mechanistically targeted, potentially curative products** 지원. 핵심: FDA 44개 CGT approvals + AI/ML analytics convergence — 규제-기술 통합 현실.

**FDA CGT 38개 Approval Assessment: 86.8% Orphan + 92.1% Expedited[14]**
Mahnum Shahzad et al.(Clinical Pharmacology & Therapeutics 2026)을 재확인한다[14]. **86.8% orphan designation**: 희귀 질환 대상. **92.1% expedited pathway**: 신속 심사. **73.7% single pivotal study**: 단일 연구 기반 승인. **44.7% surrogate endpoints exclusively**: 대리 끝점 solely 활용. **73.4% PMR/PMC**: 승인 후 의무 연구. 핵심: FDA CGT 구체적 승인 수치 — 규제 평가 체계.

**FDA CGT 14개 Pediatric + 소아 특이 고려사항[7]**
(Kunanayagam et al. — Post 2에서 상세 기술). 핵심: FDA CGT pediatric 14개 적용 + vector shedding/cellular kinetics — 소아 임상 전환 현실.

**10월 8일 Maturing(Cetin Casgevy + Chakraborty approval + Oo AI analytics) vs 오늘의 차별점**: 10/08이 **Cetin Expert Reviews**으로 Casgevy FDA 승인 이후 임상 trials 현황을, **Chakraborty Molecular Therapy Nucleic Acids**으로 Casgevy UK/MHRA + FDA dual approval을, **Oo J Clinical Pharmacology**으로 platform-aligned AI analytics를 제시했다면, 오늘은 **Oo 재확인**으로 **44개 CGT 승인(2025년 5월 기준)이라는 구체적 수치 + platform-aligned AI/ML analytics convergence**를(규제-기술 통합 현실 — Translating), **Shahzad 재확인**으로 **86.8% orphan + 92.1% expedited + 73.7% single study + 44.7% surrogate endpoints** 구체적 수치 체계(규제 평가 체계 — Translating)를, **Kunanayagam 재확인**으로 **14개 pediatric 적용 + vector shedding/cellular kinetics** 소아 고려사항(소아 임상 전환 — Translating)을 동시에 제시한다. Maturing(10/08) → 44개 approvals 구체적 수치 + AI/ML convergence + pediatric 적용 Translating(10/09).

실무 함의: Regulatory Affairs팀에서 Oo et al.의 44개 CGT 승인 현황을 gene therapy regulatory strategy에 반영해야 한다.

*출처: [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Assessment Clinical Pharmacology Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/), [Kunanayagam FDA CGT Pediatric Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)*

*#FDA #GeneTherapy #Oo #JClinicalPharmacology #44CGTApprovals #PlatformAligned #RiskBased #AIAnalytics #DoseSelection #SafetyEvaluation #DurabilityPrediction #Shahzad #ClinicalPharmacology #Therapeutics #86Percent #Orphan #92Percent #Expedited #73Percent #SingleStudy #44Percent #SurrogateEndpoints #73Percent #PMR #PMC #Kunanayagam #PediatricResearch #14Pediatric #VectorShedding #Biodistribution #CellularKinetics #CAR-T #TIL #TranslatingDay #RegulatoryApproval #ClinicalTranslation #PediatricCGT #BiomedicalAI #DailyReport*

---

### Post 7: Spatial Transcriptomics — SCLC CosMx Atlas × LAR Differential Analysis: Translating

🗺️ **[Spatial Transcriptomics] Zhang et al.로 SCLC CosMx spatial atlas — 75명 105개 검체 600K+ cells + 3개 LNM-enriched malignant subclusters + PIHs-1 survival predictor + vascular-immune crosstalk(Cell Reports Medicine 2026) + Gao et al.로 gastric cancer LAR atlas — PD1+CD27+CD8 T cells와 CD70+LAMP3+ dendritic cells 근접성 + immunotherapy biomarker(Nature Communications 2026) + Li et al.로 pan-cancer 56 LCPs + 13 niches + Niche_4(macrophage+tumor) poor prognosis + Niche_11(macrophage+immune) better survival(Cell Reports Medicine 2026): spatial transcriptomics Translating(임상 전환) 동시 확인**

Spatial transcriptomics의 **SCLC CosMx atlas + LAR differential biomarker analysis(Translating)**이 출처에서 동시에 확인된다[15][16][17].

**SCLC CosMx Spatial Atlas: 600K+ Cells + PIHs-1 + Vascular-Immune Crosstalk[15]**
Zi-Cheng Zhang et al.(Cell Reports Medicine 2026)의 연구를 재확인한다[15]. **75명 환자 105개 검체**: 600K+ cells profiling. **3개 LNM-enriched malignant subclusters**: 림프절 전이 강화 종양 하위 집합. **PIHs-1**: 독립적 survival predictor. **Vascular-immune crosstalk**: 종양 微環境 내 혈관-면역 상호작용. **Endothelial cells**: immune activation orchestrate — malignant cells avoidance + cytotoxic T cells와 functional perivascular niches 형성. 핵심: SCLC CosMx 600K+ cells + PIHs-1 + vascular-immune crosstalk — 공간 면역 atlas 임상 적용.

**Gastric Cancer LAR Atlas: PD1+CD27+CD8/CD70+LAMP3+ DCs Biomarker[16]**
Sen Gao et al.(Nature Communications 2026)을 재확인한다[16]. **PD1+CD27+CD8 T cells와 CD70+LAMP3+ dendritic cells의 공간적 근접성**: immunotherapy response 예측 biomarker. **Naïve T cell abundance + T cell activation pathways 상관관계**. 핵심: gastric cancer LAR atlas + immunotherapy biomarker — 면역 치료표적.

**Pan-Cancer 56 LCPs + 13 Niches: Niche Survival Analysis[17]**
Jiarong Li et al.(Cell Reports Medicine 2026)을 재확인한다[17]. **Niche_4(macrophage + tumor cell)**: poor prognosis + immunotherapy resistance. **Niche_11(macrophage + immune cell)**: better survival + treatment response. **Ligand-receptor analysis**: niche-shared + niche-specific interactions. 핵심: pan-cancer niche survival analysis — 생체표적.

**SCLC vs Gastric Cancer LAR Differential Analysis**: SCLC(폐소세포폐암)에서는 PIHs-1 survival predictor와 vascular-immune crosstalk이 핵심 메커니즘이며, gastric cancer(위암)에서는 PD1+CD27+CD8/CD70+LAMP3+ DCs 근접성이 immunotherapy biomarker로 작용한다. 동일 LAR(lymphocyte-aggregated region) 개념이지만 암종별로 다른 세포 구성과 메커니즘을 보인다. Pan-cancer niche analysis는 Niche_4(poor prognosis)와 Niche_11(better survival)의 보편적 패턴을 제시한다.

**10월 8일 Maturing(Li HiST + Gao LAR + Li Niche) vs 오늘의 차별점**: 10/08이 **Li Advanced Science**으로 HiST histology→spatial GEPs prediction을, **Gao Nature Communications**으로 LAR atlas를, **Li Cell Reports Medicine**으로 Niche_4/Niche_11을 제시했다면, 오늘은 **Zhang Cell Reports Medicine**으로 **SCLC CosMx 75명 105개 검체 600K+ cells + PIHs-1 + vascular-immune crosstalk**이라는 폐암 특이적 공간 atlas(Translating)를, **Gao 재확인**으로 **gastric cancer PD1+CD27+CD8/CD70+LAMP3+ DCs 근접성 biomarker**를(위암 특이적 — Translating), **Li 재확인**으로 **pan-cancer 56 LCPs + 13 niches** 보편적 패턴을(Translating) 동시에 제시한다. Maturing(10/08) → SCLC vs gastric cancer LAR differential + pan-cancer niche 보편적 패턴 Translating(10/09).

실무 함의: 면역종양학팀에서 Zhang et al.의 SCLC CosMx atlas와 Gao et al.의 gastric cancer LAR를 differential biomarker strategy로 통합해야 한다.

*출처: [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer LAR Atlas Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#SpatialTranscriptomics #Zhang #CosMx #SCLC #CellReportsMedicine #75Patients #105Specimens #600KCells #LNMMalignant #Subclusters #PIHs1 #SurvivalPredictor #VascularImmune #Crosstalk #Endothelial #CytotoxicTCells #Gao #GastricCancer #LAR #NatureCommunications #PD1 #CD27 #CD8 #CD70 #LAMP3 #DendriticCells #Immunotherapy #Biomarker #Li #PanCancer #56LCPs #13Niches #Niche4 #Niche11 #Macrophage #Tumor #Prognosis #TranslatingDay #DifferentialAnalysis #CancerSpecific #LARBiomarker #BiomedicalAI #DailyReport*

---

### Post 8: 오늘의 요약 — Translating(임상 전환) Day 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

10/09(Translating)의 핵심: Maturing(10/08)된 기술들이 **실제 임상 데이터 축적과 규제 승인으로의 이행(Translating)의 단계로 진입하며, 기술의 임상 전환 가능성을 실제 데이터로 증명하는 날**이었다.

**1. CRISPR Global Clinical Trials 700건 이상 + Off-Target Monitoring Toolkit(Şahin Molecular Therapy. Nucleic Acids 2026 + Şahin Nature Reviews Genetics 2026)**: ClinicalTrials.gov/EU Clinical Trials Register 700건 이상 등록 + 30개 이상 국가 + 기술/규제/경제적 도전 과제; preclinical-to-clinical off-target monitoring toolkit 확립 + microphysiological systems + in vivo imaging — 임상 전환 현실[1][6].

**2. AI Drug Discovery Phase I/II候补 동시 존재 + 0건 완전 마케팅 승인(Seyhan Critical Reviews Oncology Hematology 2026)**: AI-originated Phase IIa efficacy + Phase I safety stop 동시 존재 + algorithmic transparency·data quality 규제 수용성 조건 — 임상 전환 현실[2].

**3. AlphaFold3 Adversarial Vulnerability + Confidence Metrics 35%만 정확(Feldman Computational Structural Biotechnology Journal 2026)**: 40% residues 점변이나 구조 불변 + fold-switching proteins에서도 불변 + confidence 35%만 정확 + ESMFold 상대적 우위 — 임상 적용 신뢰성 과제[5].

**4. CAPTAIN Multimodal (Transcriptome + 382 Proteins) Foundation Model(Ji Nature Communications 2026)**: 4M+ cells에서 transcriptomes + 382 proteins 동시 측정 + protein imputation/expansion + cell type annotation + batch harmonization + COVID-19 immune interaction patterns — multimodal 통합 분석[10].

**5. FDA CGT 44개 Approvals + 14개 Pediatric 적용(Oo J Clinical Pharmacology 2026 + Kunanayagam Pediatric Research 2026)**: 44개 CGT 승인(2025년 5월 기준) + AI/ML dose selection·safety evaluation·durability prediction convergence; 44개 중 14개(약 32%) pediatric 적용 + vector shedding/cellular kinetics — 규제-기술 통합 현실[13][7].

**6. SCLC CosMx 600K+ Cells + PIHs-1 + Vascular-Immune Crosstalk(Zhang Cell Reports Medicine 2026)**: 75명 105개 검체 600K+ cells + 3개 LNM-enriched malignant subclusters + PIHs-1 survival predictor + vascular-immune crosstalk; SCLC vs gastric cancer LAR differential analysis + pan-cancer Niche_4/Niche_11 보편적 패턴 — 공간 면역 atlas 임상 적용[15][16][17].

10월 10일 전망: Translating된 기술들의 실제 임상 데이터 발표와 규제 승인이 핵심 변수. 특히 CRISPR global trials의 Phase III 데이터, AI候补의 Phase IIa 결과, CAPTAIN의 추가 조직 적용, SCLC vs gastric cancer LAR differential biomarker의 prospective validation이 관전이다.

*출처: [Şahin CRISPR Global Trajectory Molecular Therapy Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/), [Şahin CRISPR Monitoring Toolkit Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Mao AI Drug Discovery Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Ali AI Drug Discovery Expert Opinion Drug Discovery 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Feldman AlphaFold3 Adversarial Mutations Computational Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Ji CAPTAIN Multimodal Foundation Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Shahzad FDA CGT Assessment Clinical Pharmacology Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/), [Kunanayagam FDA CGT Pediatric Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/), [Zhang CosMx SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer LAR Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8815d6886aa485d9/), [Li Pan-Cancer Niche Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#TranslatingDay #Summary #Şahin #CRISPR #GlobalTrajectory #700Trials #MonitoringToolkit #NatureReviewsGenetics #OffTarget #Seyhan #PhaseI #PhaseII #ZeroApproval #AlgorithmicTransparency #DataQuality #Feldman #AlphaFold3 #AdversarialMutations #ConfidenceMetrics #35Percent #StructuralInvariance #Ji #CAPTAIN #Multimodal #Transcriptome #Protein #382Proteins #4MillionCells #Wang #SCMBench #FMsLessThanDMs #Cen #GenerativeAI #MultiOmics #Oo #FDA #44CGTApprovals #PlatformAligned #AIAnalytics #Shahzad #Orphan #Expedited #SurrogateEndpoints #Kunanayagam #Pediatric #14Pediatric #VectorShedding #Zhang #CosMx #SCLC #600KCells #PIHs1 #VascularImmune #Gao #GastricCancer #LAR #PD1 #CD27 #CD8 #CD70 #LAMP3 #Li #Niche4 #Niche11 #Translating #ClinicalTranslation #RealWorldData #RegulatoryApproval #BiomedicalAI #DailyReport*

---

## Sources

[1] [Şahin et al. — The landscape and trajectory of global CRISPR therapeutics. Molecular Therapy. Nucleic Acids 2026](https://consensus.app/papers/details/42b076fd7653554582553ab5be003424/)
[2] [Seyhan et al. — AI in Drug Discovery and Development. Critical Reviews in Oncology/Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)
[3] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)
[4] [Ali et al. — Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation. Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/)
[5] [Feldman et al. — Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance, Confidence Failures, and Concerns for Protein Design. Computational and Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)
[6] [Şahin et al. — Monitoring Biological Effects of Somatic Cell Genome Editing. Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/)
[7] [Kunanayagam et al. — Clinical pharmacology insights from recent cell and gene therapy approvals relevant to pediatrics. Pediatric Research 2026](https://consensus.app/papers/details/1c13548ad5be537a8451eed2c85ecd75/)
[8] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications. Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)
[9] [Abramson et al. — Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 2024](https://consensus.app/papers/details/48c459ae935b59ea9a75d3647ba7d47b/)
[10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)
[11] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)
[12] [Cen et al. — Single-Cell and Spatial Omics: Methods and Applications. MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)
[13] [Oo et al. — FDA Gene Therapy Approvals (1998–2025): Current Status, Regulatory Evolution, and Future Directions. J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)
[14] [Shahzad et al. — Assessment of United States Food and Drug Administration Approval of Cell and Gene Therapies. Clinical Pharmacology & Therapeutics 2026](https://consensus.app/papers/details/24705d5037e85bcb9d9863f1aabca040/)
[15] [Zhang et al. — Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
[16] [Gao et al. — A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8815d6886aa485d9/)
[17] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)